GB885081A - Improvements in or relating to therapeutic compositions containing (acetylsalicylic acid)-anhydride - Google Patents

Improvements in or relating to therapeutic compositions containing (acetylsalicylic acid)-anhydride

Info

Publication number
GB885081A
GB885081A GB9597/59A GB959759A GB885081A GB 885081 A GB885081 A GB 885081A GB 9597/59 A GB9597/59 A GB 9597/59A GB 959759 A GB959759 A GB 959759A GB 885081 A GB885081 A GB 885081A
Authority
GB
United Kingdom
Prior art keywords
acid
anhydride
hydrocortisone
salts
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB9597/59A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of GB885081A publication Critical patent/GB885081A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Abstract

Stable, solid preparations for oral administration comprise [acetylsalicylic acid]-anhydride and a pharmaceutically acceptable, non-alkaline diluent containing at least 3% by weight of the said anhydride of an acid substance, which diluent does not lower substantially the melting-point of the said anhydride. Specified acidic substances are sodium biphosphate, citric acid, pyridexine hydrochloride, tartaric acid, malic acid (all preferred), ascorbic acid, alkali metal bitartrates and biphosphates, glutamic acid hydrochloride, picotinic acid, acidic amino acids, salts of amino acids, succinic acid, glucuronic acid, glutaric acid, pimelic acid, malonic acid, mandelic acid, adipic acid, tricarballylic acid and mixtures thereof. The preparations may include pharmaceutically acceptable non-alkaline carriers, diluents, excipients, binders, lubricants, adhesives, disintegrators. They may be put up in solid oral dosage unit forms, e.g. tablets, capsules, pills, powder packets, effervescent granules, pilules, wafer, chewing gum, cachets, pellets and sustained release, delayed action or enteric pharmaceutical forms. Such unit dosage forms are preferably anhydrous for reasons of stability and may contain additional active ingredients, e.g. other analgesics, those specified being acetophenetidin, salicylamide, and N-acetyl-paraaminophenol, caffeine (stimulant), codeine (antitussive), cortisone, hydrocortisone, 6-methyl - D 1 - hydrocortisone, prednisone, prednisolone, their esters and salts of their acid esters (anti-inflammatory steroids), antibiotics, e.g. penicillin V, antibistaminics, reserpine and chlorpheniramine maleate.
GB9597/59A 1958-04-18 1959-03-19 Improvements in or relating to therapeutic compositions containing (acetylsalicylic acid)-anhydride Expired GB885081A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US729258A US2990328A (en) 1958-04-18 1958-04-18 Stable therapeutic compositions containing acetylsalicylic acid-anhydride

Publications (1)

Publication Number Publication Date
GB885081A true GB885081A (en) 1961-12-20

Family

ID=24930248

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9597/59A Expired GB885081A (en) 1958-04-18 1959-03-19 Improvements in or relating to therapeutic compositions containing (acetylsalicylic acid)-anhydride

Country Status (4)

Country Link
US (1) US2990328A (en)
BE (1) BE585778A (en)
GB (1) GB885081A (en)
NL (2) NL245245A (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3495001A (en) * 1968-05-27 1970-02-10 Miles Lab Effervescent compositions of acetylsalicylic acid
US4028239A (en) * 1973-06-03 1977-06-07 Lonza Ltd. Process for preventing lime deposits in a humidifier
EP0045238B1 (en) * 1980-07-29 1986-10-01 Sanofi S.A. Acid stabilized compositions of thieno-pyridine derived compounds and process for preventing degradation of such compounds
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
US4900559A (en) * 1985-12-12 1990-02-13 Briston-Myers Company Stabilized enteric coated aspirin granules and process of preparation
US6949264B1 (en) 1996-11-27 2005-09-27 Wm. Wrigley Jr. Company Nutraceuticals or nutritional supplements and method of making
US6627234B1 (en) 1998-12-15 2003-09-30 Wm. Wrigley Jr. Company Method of producing active agent coated chewing gum products
US6586023B1 (en) 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof
US7163705B2 (en) * 1998-12-15 2007-01-16 Wm. Wrigley Jr. Company Coated chewing gum product and method of making
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6355265B1 (en) 1999-04-06 2002-03-12 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6426090B1 (en) * 1999-04-06 2002-07-30 Wm. Wrigley Jr. Company Over-coated product including tableted center and medicament
US6773716B2 (en) 1999-04-06 2004-08-10 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US7935362B2 (en) * 1999-04-06 2011-05-03 Wm. Wrigley Jr. Company Over-coated product including consumable center and medicament
US6322806B1 (en) 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center
US20020159956A1 (en) * 1999-04-06 2002-10-31 Ream Ronald L. Over-coated chewing gum formulations
US6645535B2 (en) 1999-09-02 2003-11-11 Wm. Wrigley Jr. Company Method of making coated chewing gum products containing various antacids
US6569472B1 (en) 2000-09-01 2003-05-27 Wm. Wrigley Jr. Company Coated chewing gum products containing antacid and method of making
US6663849B1 (en) 2000-09-01 2003-12-16 Wm. Wrigley Jr. Company Antacid chewing gum products coated with high viscosity materials
US6541048B2 (en) 1999-09-02 2003-04-01 Wm. Wrigley Jr. Company Coated chewing gum products containing an acid blocker and process of preparing
US9387168B2 (en) 1999-09-20 2016-07-12 Jack Barreca Chewing gum with tomatidine
AU3885201A (en) 1999-09-20 2001-04-24 Mastercare Diet and weight control gum and sucker
US9253991B2 (en) 1999-09-20 2016-02-09 Jack Barreca Chewing gum with B vitamins
DK1241949T3 (en) * 1999-12-30 2012-07-30 Wrigley W M Jun Co RELEASE OF LIPOFILE ACTIVE SUBSTANCES FROM CHEMICAL GUM
US6350480B1 (en) * 1999-12-30 2002-02-26 Wm. Wrigley Jr. Company Chewing gum product including a hydrophilic gum base and method of producing
US7115288B2 (en) * 2000-06-09 2006-10-03 Wm. Wrigley Jr. Company Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener
US6572900B1 (en) 2000-06-09 2003-06-03 Wm. Wrigley, Jr. Company Method for making coated chewing gum products including a high-intensity sweetener
US6444241B1 (en) 2000-08-30 2002-09-03 Wm. Wrigley Jr. Company Caffeine coated chewing gum product and process of making
US6579545B2 (en) 2000-12-22 2003-06-17 Wm. Wrigley Jr. Company Coated chewing gum products containing an antigas agent
PT3509567T (en) * 2017-08-04 2021-05-13 Poli Md S R L Medical device for the treatment of hpv cutaneous infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US922766A (en) * 1907-10-31 1909-05-25 Farbenfab Vorm Bayer F & Co Anhydrid of acyl salicylic acid.
US2888382A (en) * 1957-10-28 1959-05-26 Upjohn Co Therapeutic composition and process

Also Published As

Publication number Publication date
NL245245A (en)
US2990328A (en) 1961-06-27
NL121097C (en)
BE585778A (en)

Similar Documents

Publication Publication Date Title
GB885081A (en) Improvements in or relating to therapeutic compositions containing (acetylsalicylic acid)-anhydride
US6706255B2 (en) Liquid pharmaceutical compositions comprising thyroid hormones
ES403435A1 (en) Slow release pharmaceutical compositions
NO863796L (en) PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICAL PREPARATIONS WITH EXTENDED EFFECTIVE TIME.
EP0274845B1 (en) Stable solid pharmaceutical composition containing ibuprofen and codeine
IE871981L (en) Programmed release formulation.
IE832358L (en) Compositions comprising a pyrimidopyrimidine derivative
DE3872739D1 (en) SLOW RELEASE MEDICINAL PRODUCTS.
ES2590914T3 (en) Hormonal preparation containing a combination of ethinyl estradiol and chlormadinone acetate
EP0719148B1 (en) Oral water soluble pharmaceutical compositions containing estrone derivative and calcium salt
JPS62209025A (en) Medicne synthetic article continuously releasing quickly effective component and blending method
US3039922A (en) Method of administering tablets having decongestant and anti-histaminic activity
EP0449426B1 (en) A pharmaceutical composition
US3676549A (en) Administration of alkali metal salts of salicylamide
US3152045A (en) Composition and method for angina pectoris therapy
GB2175804A (en) Treating cramp
US7199153B2 (en) Pharmaceutical composition comprising paracetamol and niflumic acid
US3567828A (en) Organic compounds
JPH0113449B2 (en)
US3629471A (en) Tranquilizing compositions and methods
GB1357813A (en) Effervescent composition for the treatment of heart diseases
ES377723A1 (en) Improvements in pharmaceutical compositions
GB881377A (en) Oral-pharmaceutical preparations containing 6-chloro-7-sulphamyl-3:4-dihydro-1:2:4-benzothia-diazine-1:1-dioxide
GB1110397A (en) Ephedrine composition
EP0367509A3 (en) Formulations